Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
Atherosclerosis. 2021 Dec;339:48-54. doi: 10.1016/j.atherosclerosis.2021.10.007. Epub 2021 Oct 18.
Coronary artery calcium (CAC) scores have been shown to be associated with CVD and cancer mortality. The use of CAC scores for overall and lung cancer mortality risk prediction for patients in the Coronary Artery Calcium Consortium was analyzed.
We included 55,943 patients aged 44-84 years without known heart disease from the CAC Consortium. There were 1,088 cancer deaths, among which 231 were lung cancer, identified by death certificates with a mean follow-up of 12.2 ± 3.9 years. Fine-and-Gray competing-risk regression was used for overall and lung cancer-specific mortality, accounting for the competing risk of CVD death and after adjustment for CVD risk factors. Subdistribution hazard ratios (SHR) were reported.
The mean age of all patients was 57.1 ± 8.6 years, 34.9% were women, and 89.6% were white. Overall, CAC was strongly associated with cancer mortality. Lung cancer mortality increased with increasing CAC scores, with rates per 1000-person years of 0.2 (95% CI: 0.1-0.3) for CAC = 0 and 0.8 (95% CI: 0.6-1.0) for CAC ≥400. Compared with CAC = 0, hazards were increased for those with CAC ≥400 for lung cancer mortality [SHR: 1.7 (95% CI: 1.2-2.6)], which was driven by women [SHR: 2.3 (95% CI: 1.1-4.8)], but not significantly increased for men. Risks were higher in those with positive smoking history [SHR: 2.2 (95% CI: 1.2-4.2)], with associations driven by women [SHR: 4.0 (95% CI: 1.4-11.5)].
CAC scores were associated with increased risks for lung cancer mortality, with strongest associations for current and former smokers, especially in women. Used in conjunction with other clinical variables, our data pinpoint a potential synergistic use of CAC scanning beyond CVD risk assessment for identification of high-risk lung cancer screening candidates.
冠状动脉钙(CAC)评分与心血管疾病(CVD)和癌症死亡率相关。本研究旨在分析冠状动脉钙联合会(CAC 联合会)中 CAC 评分在预测患者总体和肺癌死亡率中的作用。
我们纳入了来自 CAC 联合会的 55943 名年龄在 44-84 岁、无已知心脏病的患者。通过死亡证明确定了 1088 例癌症死亡,其中 231 例为肺癌,平均随访 12.2±3.9 年。采用 Fine-Gray 竞争风险回归分析评估总体和肺癌特异性死亡率,同时考虑 CVD 死亡的竞争风险,并在调整 CVD 危险因素后进行分析。报告了亚分布危险比(SHR)。
所有患者的平均年龄为 57.1±8.6 岁,34.9%为女性,89.6%为白人。总体而言,CAC 与癌症死亡率密切相关。肺癌死亡率随 CAC 评分的增加而增加,每 1000 人年的发生率分别为 CAC=0 时的 0.2(95%CI:0.1-0.3)和 CAC≥400 时的 0.8(95%CI:0.6-1.0)。与 CAC=0 相比,CAC≥400 的患者肺癌死亡风险增加[SHR:1.7(95%CI:1.2-2.6)],这主要归因于女性[SHR:2.3(95%CI:1.1-4.8)],但在男性中无显著增加。有阳性吸烟史的患者风险更高[SHR:2.2(95%CI:1.2-4.2)],其相关性主要归因于女性[SHR:4.0(95%CI:1.4-11.5)]。
CAC 评分与肺癌死亡率升高相关,与当前和既往吸烟者的相关性最强,尤其是女性。结合其他临床变量,我们的数据表明 CAC 扫描除了用于 CVD 风险评估外,还可能用于识别高危肺癌筛查人群,从而实现潜在的协同作用。